Dr. Barbara SCHÜTT,Dr. Marcus-Hillert SCHULTZE-MOSGAU,Dr. Andreas KAISER
申请号：
CL2015003014
公开号：
CL2015003014A1
申请日:
2015.10.09
申请国别(地区):
CL
年份:
2016
代理人:
摘要：
Pharmaceutical composition comprising a progesterone receptor antagonist, (11 u00df, 17 u00df) - 17 - hydroxy - 11 - [4 - (methylsulfonyl) phenyl] - 17 - (pentafluoroetil) estra - 4.9 - dien - 3-one at a dosage of between approximately 0.5 and 5 mg and more particularly of 2 mg.In addition, The Invention is directed to the use of a Pharmaceutical composition for the prophylaxis and / or treatment of gynecological diseases such as uterine fibroids (fibroids, uterine leiomyoma, endometriosis or former menstrual Bleeding)COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE 0,5-5 mg DE (11?,17?)-17-HIDROXI-11-[4-(METILSULFONIL)FENIL]-17-(PENTAFLUOROETIL)ESTRA-4,9-DIEN-3-ONA； FORMA DE DOSIFICACIÓN ORAL； USO PARA TRATAR Y/O PREVENIR UNA ENFERMEDAD GINECOLÓGICA, TAL COMO, FIBROIDES EN EL ÚTERO, ENDOMETRIOSIS O HEMORRAGIAS MENSTRUALES EXCESIVAS.
